AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is conducting a Phase I study titled ‘A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234.’ The study aims to evaluate the pharmacokinetics, safety, and tolerability of AZD6234 in patients with varying degrees of renal impairment compared to healthy controls. This research is significant as it could inform dosing guidelines for patients with renal issues.
The intervention being tested is AZD6234, a drug administered as a single subcutaneous dose. It is intended to assess how renal impairment affects the drug’s behavior in the body, its safety, and tolerability.
The study is designed as a non-randomized, open-label, parallel-group trial. Participants are divided into cohorts based on their renal function, including those with end-stage renal disease, severe, moderate, and mild renal impairment, and healthy controls. The primary purpose is treatment-focused, with no masking involved.
The study began on February 24, 2025, and the latest update was submitted on August 5, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
This update could impact AstraZeneca’s stock performance positively if the results show promising safety and efficacy, potentially boosting investor confidence. In a competitive pharmaceutical landscape, advancements in renal impairment treatments could position AstraZeneca favorably against its peers.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.